- Home
- RGLS vs CMPX Comparison
RGLS vs CMPX Comparison
Compare RGLS & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGLS
- CMPX
- Stock Information
- Founded
- RGLS 2007
- CMPX 2014
- Country
- RGLS United States
- CMPX United States
- Employees
- RGLS N/A
- CMPX N/A
- Industry
- RGLS Biotechnology: Pharmaceutical Preparations
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- RGLS Health Care
- CMPX Health Care
- Exchange
- RGLS Nasdaq
- CMPX Nasdaq
- Market Cap
- RGLS 106.7M
- CMPX 236.7M
- IPO Year
- RGLS 2012
- CMPX N/A
- Fundamental
- Price
- RGLS $1.59
- CMPX $1.78
- Analyst Decision
- RGLS Strong Buy
- CMPX Strong Buy
- Analyst Count
- RGLS 6
- CMPX 3
- Target Price
- RGLS $10.33
- CMPX $7.67
- AVG Volume (30 Days)
- RGLS 391.3K
- CMPX 491.3K
- Earning Date
- RGLS 11-11-2024
- CMPX 11-07-2024
- Dividend Yield
- RGLS N/A
- CMPX N/A
- EPS Growth
- RGLS N/A
- CMPX N/A
- EPS
- RGLS N/A
- CMPX N/A
- Revenue
- RGLS N/A
- CMPX $850,000.00
- Revenue This Year
- RGLS N/A
- CMPX N/A
- Revenue Next Year
- RGLS N/A
- CMPX $747.71
- P/E Ratio
- RGLS N/A
- CMPX N/A
- Revenue Growth
- RGLS N/A
- CMPX N/A
- 52 Week Low
- RGLS $1.08
- CMPX $0.77
- 52 Week High
- RGLS $3.79
- CMPX $2.34
- Technical
- Relative Strength Index (RSI)
- RGLS 53.16
- CMPX 52.22
- Support Level
- RGLS $1.39
- CMPX $1.81
- Resistance Level
- RGLS $1.68
- CMPX $1.80
- Average True Range (ATR)
- RGLS 0.12
- CMPX 0.13
- MACD
- RGLS 0.01
- CMPX -0.03
- Stochastic Oscillator
- RGLS 68.97
- CMPX 34.88
About RGLS Regulus Therapeutics Inc.
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.